• Multi-state cannabis operator Red White & Bloom Brands is developing opportunities strategically in sizable cannabis markets such as Michigan, Florida, Illinois, California, Arizona, Oklahoma and Massachusetts
• The company recently announced it has secured full licensing for manufacturing both medical and adult use cannabis products in Michigan, one of its key markets
• Red White & Bloom has closed on a lease assignment for a 15,000-square-foot manufacturing, processing and distribution facility in the state
• In Florida, Red White & Bloom settled a CAD$5.1 million debt at a favorable conversion price, granting the company an accounting gain of approximately CAD$2.3 million

As Michigan enters into its third year under legislation allowing the legal sale of adult “recreational use” cannabis, multi-state cannabis operator Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) is celebrating corporate developments that include full licensing for manufacturing both medical and adult use cannabis products in the state. “We will be expanding the wildly popular Platinum Vape brand to include gummies and chocolates to capitalize on the existing brand equity we command in Michigan,” CEO and Chairman Brad Rogers stated in a Jan. 18 announcement (https://ibn.fm/kb0Ox). Red White & Bloom Brands, also known simply as RWB, received adult recreational use prequalification status for manufacture in Michigan in September, allowing it to begin marketing itself to the state’s approximately 10 million residents. The company has closed on a lease assignment for a 15,000-square-foot manufacturing, processing and distribution facility in Warren, Mich., which is part of RWB’s strategic planned acquisition of 18 Michigan dispensaries, four cultivation facilities and other significant real estate announced in September (https://ibn.fm/gdxMJ). Eight of the dispensaries are already open with the remaining 10 in process, a January High Times article reports (https://ibn.fm/sND8F). “This Warren facility allows us to centralize distribution for our ‘house of premium brands’ in Michigan and finally report all of our Platinum Vape(TM) wholesale sales on a much less confusing and straightforward basis,” Rogers stated. “The facility provides the production capacity to expand sales of our award-winning brands from the 250+ Michigan dispensaries that carry them to the state’s 400+ dispensaries.” Platinum Vape, also referred to as PV by the company, recorded a 93 percent YOY increase in revenues as of the close of the company’s Q3 period, gaining it recognition as a top-selling brand in the state by LeafLink’s marketplace analysis (https://ibn.fm/LLC4c). Michigan’s cannabis sales were expected to approach $2 billion last year with a run-rate that falls behind only California and Colorado. RWB’s operations in California have granted its gummies, chocolates and premium cannabis flower popularity and the developments in Michigan will expand those products through Platinum Vape beyond California for the first time. RWB also operates in Florida, Illinois, Massachusetts and Arizona. Its Florida operations have progressed rapidly in recent months, where the installation of 30 grow pods at the company’s 45,000-square-foot Apopka cultivation site heralded the beginning of Phase 2 expansion for the company there (https://ibn.fm/cECpn). In addition, Red White & Bloom announced Dec. 30 that it had refinanced the principal amount of a debt established in connection with RWB Florida LLC’s acquisition of all of the issued and outstanding shares of Acreage Florida, Inc. At the same time, the company settled a CAD$5.1 million (US$4.0 million) debt at a favorable conversion price, granting the company an accounting gain of approximately CAD$2.3 million (US$1.8 million) (https://ibn.fm/LUIdJ) and helping RWB to better position itself for growth in the coming year. For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

• The global cannabinoid-based pharmaceuticals market is projected to be valued at $50 billion by 2029
• InMed is leading the industry, laying down the foundation in manufacturing and clinical development of rare cannabinoids
• It is shedding light on the potential of rare cannabinoids and laying the groundwork on how to tap into the industry’s growth

It is projected that by 2025, the global cannabis market will be valued at around $146 billion, up from just $20.47 billion in 2020. This sector is experiencing tremendous growth, particularly considering that there are over one hundred known cannabinoids, including rare ones that are quickly taking over and will soon dominate the cannabis market (https://ibn.fm/2NLFN). The potency of rare cannabinoids has given them powerful health benefits, hence their demand within the cosmetics, food and beverage, health, and wellness sectors. However, one that stands above the rest is the pharmaceuticals sector. It is growing at a rapid pace and is projected to be valued at $50 billion by 2029. An enterprise that is helping to define rare cannabinoids in the pharmaceutical sector is InMed Pharmaceuticals (NASDAQ: INM). This enterprise is laying down the foundation in the manufacturing and clinical development of rare cannabinoids. It is a trailblazer, a pioneer defining the value of rare cannabinoids in this sector and just how integral they are in pushing the pharmaceutical industry forward. InMed’s most advanced compound, INB-755, has already proven helpful in treating epidermolysis bullosa, a severe genetic disorder. The compound has undergone Phase 1 clinical trials with impressive results, and global Phase 2 clinical trials are underway. InMed is also working on its INM-008 compound for the treatment of glaucoma and is currently evaluating different formulations to deliver ocular cannabinoids into the eye. InMed studies were also just recently published in an internal peer-review journal providing credibility to the data. InMed is not just focusing on rare cannabinoid research but also investing time and resources into its manufacturing process. So far, this process allows for cannabinoid synthesis to create compounds in the laboratory that are bioidentical to those derived from the cannabis plant. In addition, this move recognizes the limited availability of rare cannabinoids, making it economically impractical to extract directly from the plants for pharmaceutical use. Rare cannabinoids are already being recognized for their versatility in application and how effective they are at what they do. Rare cannabinoids have the ability to deliver differentiated products, including augmenting existing CBD-based products, to consumers in the health and wellness marketplace. With companies such as InMed at the forefront of rare cannabinoid research, specifically in the pharmaceutical industry, they are shedding light on the potential of such products. They are also laying the groundwork for tapping into a sector that is expected to grow in value significantly over the next few years. Most importantly, these companies, InMed specifically, are positioning themselves to reap big from the inevitable boom that will define the sector. For more information, visit the company’s website at www.InMedPharma.com. NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

• Bitcoin is becoming increasingly popular, having already been adopted as legal tender by El Salvador in 2021, and being bartered for incentives in other areas, such as Rio offering a 10% discount when taxes are paid in Bitcoin
• Instead of spending, some crypto owners (HODLers) are holding crypto in high-yield savings accounts, collecting up to 12% APY interest – benefiting despite the volatility of the coin
• LQwD has seen exponential growth since its completed acquisition in June 2021, with a current Bitcoin holding of almost 150 tokens
• Lightning Network has also grown significantly over the past year in terms of number of nodes, Bitcoin capacity and payment channels

Since the beginning of 2020, Bitcoin has appreciated in value by over 700%, helping hedge against inflation. While fiat currencies are printing more and more money to keep up with spending, Bitcoin is limited to 21 million BTC. Even with Bitcoin having a high value, it is possible to purchase partial amounts of the coin, as it is divisible by 1 million. Although considered rather volatile, Bitcoin is one currency that (in the long-term) could stand up against the inflation rates created by the mass production of other fiat currencies, like euros and the U.S. dollar (https://ibn.fm/yhrTb). With the volatility of Bitcoin in question, some people who have purchased the coin have decided to do nothing with it except hold it. These people have been given the name HODLers, meaning they hold crypto, often choosing to use a high-yield savings account. These accounts have almost a negligible bank deposit interest rate (0.5%), but the high-yield crypto savings accounts produce interest rates of up to 12% annual percentage yield (“APY”). Even so, Bitcoin is growing in popularity, with more countries worldwide considering the use of cryptocurrency as legal tender. In 2021, El Salvador was the first to implement Bitcoin as legal tender across the country. Even the U.S. administration made it clear that it would not ban cryptocurrency. Some states or townships have openly embraced Bitcoin, such as the city of Rio that is offering taxpayers a 10% discount when paying their taxes with the cryptocurrency. Uniquely positioned to further drive Bitcoin adoption is LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), a fintech company that has focused on creating enterprise-grade infrastructure for Bitcoin adoption, making it easier to complete transactions with the crypto coin on the Lightning Network. The Lightning Network is a second-layer protocol that sits above the bitcoin blockchain. LQwD’s proprietary platform as a service (“PaaS”), which leverages Lighting Network technology, was introduced to the public on November 17, 2021, and offers users lower transaction fees and faster transaction settlement times. Formerly known as Interlapse Technologies Corp., LQwD’s acquisition was completed in June 2021 and since then, the company has seen exceptional growth – a trend expected to continue into 2022. The company grew alongside the Lightning Network, which also achieved several major milestones since January 2021: node growth of 105% for node establishment from 770 to over 15,000, increased Bitcoin capacity from 1,125 BTC to almost 3,000 BTC – up 160% to September 30, 2021, and a 92% increase in the number of payment channels, totaling more than 73,000 up from the initial 38,000. “The remarkable growth of the Lightning Network has validated LQwD’s reason to be hyper-focused on Lightning, and I look forward to continuing to expand our business on this rapidly growing global payment network,” LQwD CEO Shone Anstey said (https://ibn.fm/bC3NA). The company’s highlights for the last six months of 2021 include:

• A non-brokered private placement with proceeds of CAN $5 million in June 2021
• An offering of 23 million units which produced proceeds of C$8,050,000 (US$6.4 million) at the end of October 2021
• The cumulative acquisition of 150 Bitcoin as an operating asset for the company

LQwD plans to continue leveraging its position as a public company, enhancing trust in its products and services, and leveraging its shares to attract and retain top industry talent – bringing vast opportunities and marketing segments for digital payments and financial services at a global scale. For more information, visit the company’s website at www.LQwDFinTech.com. NOTE TO INVESTORS: The latest news and updates relating to LQWDF are available in the company’s newsroom at https://ibn.fm/LQWDF

• SRAX will host their inaugural Metals & Mining Conference on January 27, 2022
• The conference will be held on Sequire’s Virtual Events platform and will play host to over 70 companies along with a series of industry experts and thought leaders
• The event marks the latest iteration of SRAX’s extensive conference series, which saw them host the flagship LD Micro Main Event in October 2021

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, has announced that it will be hosting the inaugural Sequire Metals & Mining Conference, a one-day investor event featuring a number of prominent public mining companies and industry experts, on its Sequire Virtual Events platform on January 27, 2022 (https://ibn.fm/0uDUG). The metals and mining sector has become increasingly crucial to the proper functioning and health of the global economy. Given the robust level of interest surrounding the sector, SRAX have sought to host a full day of networking and learning featuring some of the premier innovators within the metals and mining space. The event will be hosted on the company’s proprietary Sequire platform and will feature presentations, one-on-one meetings with company executives, and a series of influential industry speakers and thought leaders. This year’s inaugural Metals & Mining Conference will feature approximately 70 companies in attendance, divided into four distinct tracks (https://ibn.fm/46WMi). Each of the companies in attendance will carry out a 25-minute presentation, thus providing them with an opportunity to share their stories and operational highlights with the thousands of conference delegates in attendance. Investors attending the virtual event will be able to meet with corporate management teams in a live, one-on-one, or small group meeting format to gain further insights as to an individual company’s operational highlights. “This has been one of the fastest growing events we have ever hosted. Its clear companies are eager to tell their story and give the latest company updates, and investors are registering to listen. We look forward to hosting everyone for our first event of 2022 and kicking off the year in a strong way,” said Morgan-Lea Fogg, Vice President of Community & Events at SRAX. Boasting a network of over nine million influential, forward-thinking investors and shareholders, the Sequire platform has established a robust reputation as a venue where investors can congregate to learn, share, and network on a wide range of industry related topics. The Sequire Metals & Mining Conference Event is the latest highlight within an extensive conference series designed by SRAX and Sequire to offer added value to their budding investor community. Sequire has previously played host to major events, such as the 2021 LD Micro Event (https://ibn.fm/MF8Lo), a prominent three-day joint in-person and virtual investor conference, which was held between October 12-14, 2021. In addition to featuring 139 small- and mid-cap companies in attendance, the event also played host to a myriad of influential keynote speakers and thought leaders. Sequire’s extensive and diverse conference series ranks amongst the various strategies employed by parent company, SRAX, to augment and streamline their operations over the past several months. Other measures undertaken by the company include naming entrepreneur and 2020 presidential candidate, Brock Pierce, to the company’s board of directors as well as divesting an equity stake in TI Health (formerly known as SRAXmd). Through its constant focus on adding value for the millions of investors on its Sequire platform, as well as for their near 200 publicly listed corporate subscribers, the Sequire platform has established a strong reputation as a venue where investors congregate to learn, share, and network on a wide range of industry related topics. The popularity and success of the upcoming Sequire Metals & Mining Conference is yet another testament to the platform’s ever-increasing prominence within the global investor community. For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• CryptoHawk is designed to monitor, analyze cryptocurrencies to predict price trends and alerts traders when change occurs
• DIGIMax recently added Altcoin Radar to its CryptoHawk trading tools arsenal to detect unexpected fast rises

The world of crypto trading is known for its volatility, with wild fluctuations within the market. DigiMax Global’s (CSE: DIGI) (OTC: DBKSF) CryptoHawk, one of the world’s most powerful and complete crypto price prediction indicator tools available, can provide a bird’s eye view of crypto investing, resulting in more efficient predictions (https://ibn.fm/u5jnj). As cryptocurrencies grow in popularity, new investors entering the space will soon find out that crypto price forecasting is extremely challenging due to the market’s price volatility and dynamism. Those fast-fluctuating numbers have made millionaires of a lucky few, but delivered crushing losses to others. “Since the beginning of October, Bitcoin had been above $50,000 — for many, a sign of an ongoing bull market — but Bitcoin’s flash crash last weekend — in part because of substantial leverage trading — surprised some,” reported a recent Decrypt article, which noted that “$1.79 billion of Bitcoin was liquidated within an hour, sending its value down to around $47,000 on Friday. Bitcoin prices returned to $50,000 around noon ET on Sunday after a week of hovering in the high $40,000s.” CryptoHawk attempts to reduce some of these price forecasting challenges and is specifically designed to analyze crypto price trends and alert traders about key components that indicate the time may be right to enter the market. The innovative platform also helps traders decide whether to buy, sell, or hold the cryptocurrencies to reap the maximum benefits. It predicts crypto price trends by using deep learning algorithms, which can discover hidden patterns from data, integrate them, and create far more efficient predictions. Most recently, DigiMax added Altcoin Radar to its CryptoHawk trading tools kit (https://ibn.fm/6pU7u). “The AI-driven Altcoin Radar lists the top 100 Altcoins that meet two essential criteria,” the company announced. “[First], the coin is available on a credible cryptocurrency trading platform; and [second], the coin is monitored for attributes that give it some likelihood of a near-term significant price increase. “The top-monitored coins are listed in order of their coin momentum score,” the announcement continued. “The Altcoin Radar separates the coins into two lists. One list showcases ‘blipping’ coins on the radar that Altcoin Radar indicates as having the highest likelihood of rising in the market. The other list is continuously being monitored for changes in coin momentum. When applying and testing our new AI feature, we detected the early rise of both Shiba Inu and Dogecoin.” The Altcoin Radar addition is the third predictive tool added to DIGI’s CryptoHawk arsenal, designed to create a complete and powerful AI system that supports three different trading styles. CryptoHawk also features Long-Short Indicators, designed for day trading, which detect a price direction that is assessed on the hour for a selection of established cryptocurrencies, and Trend Watch, designed for swing trading, which provides a rolling four-day outlook for a target high and low price prediction. CryptoHawk detects when the cryptocurrency’s current price reaches its next target prediction for the investor to act on their trading strategy. “The CryptoHawk AI engine adds a considerable level of additional social media and crypto industry data,” the company noted. “By combining these data sources for Altcoin Radar, traders will gain higher confidence in our predictions. DigiMax is an artificial-intelligence-technology company committed to unlocking the potential of disruptive technologies by providing advanced financial, predictive and cryptocurrency solutions across various verticals. DigiMax is an official IBM partner, and the company’s engineering team has extensive experience in machine learning, neural language processing and AI. For more information, visit the company’s website at www.DigiMax-Global.com. NOTE TO INVESTORS: The latest news and updates relating to DBKSF are available in the company’s newsroom at https://ibn.fm/DBKSF

Microdose Psychedelic Insights is a cutting-edge media firm that aims to bring the psychedelics sector to the forefront of contemporary medicine by developing appealing content, disseminating financial analyses, and holding interesting industry events. On January 27, 2022, Microdose will host the Psychedelic Capital January Edition. Attendees will have access to the top firms, most recent IPOs, newest opportunities, and most in-depth market knowledge in the rapidly rising psychedelic medicine sector at the virtual event. Key Points Covered This month’s conference features dynamic presentations from Heroic Hearts Project, Entheo Digital, PurMinds NeuroPharma, HAVN Life Sciences Inc. and panel discussions on topics of Public vs Private Markets, and What Will 2022 Look Like. Heroic Hearts Project offers a proprietary program to veterans who are interested in pursuing psychedelic treatment options. Heroic Hearts Project primarily works with ayahuasca retreat centers due to the powerful effect it has shown to have on healing PTSD. The Heroic Hearts Project program has been designed to ensure veterans get the most out of this valuable opportunity and are set up for success when they return home. Entheo Digital Entheo Digital is a digital therapeutics company pursuing the creation of a wellness technology marketplace at the intersection of psychedelic therapy and experiential medicine. The company is growing the accessibility and scalability of psychedelic therapy with immersive virtual experiences. PurMinds NeuroPharma PurMinds NeuroPharma is pursuing breakthrough solutions for devastating neurological disorders with a special emphasis on neurodegenerative diseases. We strive to deliver the right drugs to the right patients by utilizing technology and championing next generation drug development approaches. Drug development for neurological disorders has been marred with failure due to imperfect modelling of human diseases in pre-clinical studies and inadequate stratification within patient recruitment for clinical trials. We use multi-omics analyses of diseased and healthy Human iPSC-derived neurons to better understand the pathophysiology of neurodegenerative diseases, which enables us to design personalized, precision neurotherapeutics. HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind. Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle. Explore the Schedule *All times are Eastern Standard Time Zone. 1:30pm: Introduction Featuring Patrick Moher and Richard Skaife. 1:45pm: Doing Good Presentation – Heroic Hearts Project Featuring Jesse Gould. 2:05pm: Entheo Digital Featuring Robin Arnott, and Sandeep Prakash. 2:40pm: Public vs Private Markets Featuring Richard Skaife, Bill O’Hara, and Matthew King. 3:15pm: PurMinds NeuroPharma Featuring Susan Chapelle, and Janet Qi. 3:50pm: What Will 2022 Look Like Featuring Cody Shandraw, Sara Brittany Somerset, Tesla La Touche, Doug Drysdale. 04:25pm: HAVN Life Sciences Featuring Tim Moore. Additional information about the Psychedelic Capital: January 2022 Conference, as well as details for registration, can be found on the Psychedelic Capital conference website at the following link: https://microdose.buzz/pressrelease Why You Should Attend Attendees will be able to form contacts, network with professionals from throughout the psychedelics industry, and learn about intriguing and breakthrough pre-IPO investment opportunities in the field at the conference. For more information regarding the Psychedelic Capital Jan 27 conference, including registration and complimentary tickets, please visit https://microdose.buzz/pressrelease.

Freakish Midwest tornados, devastating wildfires, extreme droughts, abnormal floods – all signal the onset of a changing global climate. There’s overwhelming concern about climate change, but it’s difficult to achieve consensus on actions to mitigate it. The COP 26 UN Climate Change Conference last November was a step in the right direction, spurring global commitments and serving a clear notice that the era of coal is rapidly coming to an end. Three dozen countries, including the United States, pledged to stop funding fossil fuel projects abroad by the end of this year, and more than 40 countries promised to phase out coal-fired power, the planet’s most carbon-intensive energy source. Largely due to capitalism, the shift to renewables is building a real head of steam. However, renewables alone cannot meet global energy needs. Solar and wind provide clean renewable energy when the sun is shining or the wind is blowing, but, if it’s cloudy and calm, they don’t produce much of anything. Since the technology hasn’t been developed to easily and cheaply store electricity in large quantities, other energy sources must fill this intermittency gap. Without 24/7 base-load producers, there currently isn’t enough consistent uninterrupted energy to sufficiently supply the grid, no matter how many solar or wind facilities get tacked on. Excluding fossil fuels, there’s currently only one real viable option for reliable 24/7 base-load electricity – nuclear power. Clean, safe and affordable, nuclear power is the only known low-carbon reliable power source that can meet both current and future base-load electricity demands while reducing air pollution and mitigating climate change. U.S. nuclear power plants already generate nearly 20% of the U.S.’s electricity and 55% of its carbon‐free electricity. Nuclear power requires use of U3O8, the most stable form of uranium oxide. It is commonly found in nature, but extraction is only economically viable from rich deposits. The largest producer of uranium in the U.S. is Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR). The leading U.S. diversified uranium miner, Energy Fuels is also the country’s leading conventional producer of vanadium and, importantly, began production of rare earths in 2021 at a stage more advanced than any other U.S. company. These are all designated as critical minerals by the U.S. government for national security as well as economic growth and stability. Energy Fuels’ uranium production portfolio stands apart in the world. The company has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and are uniquely positioned to increase production to meet new demand – and demand is expected to surge along with uptake. There are substantial direct drivers to increased uranium demand. Nuclear already provides a large portion of the nation’s electricity, and any real increase in electricity demand would require significant new nuclear capacity. It’s also the only known clean, safe, reliable base-load provider of carbon-free electricity in the transition to renewables. In addition and of substantial note, China is planning at least 150 new nuclear reactors in the next 15 years and has started building its first small modular reactor (“SMR”). Small modular reactors represent a new approach and could change the landscape of nuclear power. This “new generation of nuclear reactors could hold the key to a green future”, as heralded and headlined in a recent Time magazine article. Current nuclear power plants run most efficiently at full blast, which makes it difficult to adapt to a grid increasingly powered by variable sources (again, not every day is sunny or windy). This next generation of nuclear technology will be more flexible, able to adapt and respond quickly to the ups, downs and intermittency in supply and demand. The new generation of reactors differentiate from old-school reactors in size, scale, approach, safety, and application. With few operators in the space, the technology and opportunity have attracted notable interest and financial backing from Silicon Valley, Bill Gates, and the U.S. Department of Energy. Smaller reactors could be built in factories, ensuring quality control, and deployed to remote locations that lack wind, sun or other resources for energy production. They also can be purpose built to need, customized for use, and easily scaled. This exciting new technology to achieve carbon-free energy has potential to supplement other energy sources or even become a dominant method of energy production. Uranium demand should increase in lock step as the technology scales. In its annual long-term analysis on the future of the energy economy, BloombergNEF outlines three climate scenarios that achieve net-zero emissions by 2050. Each of Bloomberg’s scenarios describe major transformations in the primary energy supply, and nuclear remains a critical portion of all three scenarios. In the scenario that reduces fossil fuel use the most, nuclear makes up a whopping 66% of primary energy in 2050, compared with 5% today. This all adds up to a nuclear power renaissance, and demand for uranium is likely to remain unabated as the entire world continues to decarbonize. Much maligned uranium could be what ultimately saves the planet. For more information, visit the company’s website at www.EnergyFuels.com. NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• The Harris Poll conducted a survey on behalf of Delic Holdings, polling 2,037 adults ages 18 and older, 953 of whom suffer from anxiety/depression/PTSD
• The survey revealed that 65% of Americans living with anxiety/depression/PTSD believe that psychedelic medicine should be available to patients with treatment-resistant conditions
• 66%, 62%, and 56% are open to pursuing ketamine, psilocybin, and MDMA, respectively, to treat anxiety/depression/PTSD if these psychedelic drugs were each proven more effective than prescription medication with fewer side effects

Though the U.S. government has not yet federally recognized a medical use for most psychedelic drugs, research by renowned universities and companies like Delic Holdings (CSE: DELC) (OTCQB: DELCF) has been ongoing, partly charging what has come to be referred to as the psychedelic renaissance. Research has so far shown that the drugs – ketamine, psilocybin, MDMA (also known as ecstasy), and LSD – could potentially remedy mental conditions such as post-traumatic stress disorder (“PTSD”), depression, and addiction. There is also growing evidence that psychedelic drugs’ action in the brain differs from addictive drugs’ (https://ibn.fm/ioaZy). “One of the key mooted advantages of psychedelics over existing drugs is that they work holistically to make the neuroplastic brain more malleable, therefore freeing people from long-held beliefs and memories – opening them evermore to new concepts and states of mind. Thus, they allow the brain to reset and rewire itself, rather than simply dampening down symptoms and even causing serious side-effects,” reads an article published in The Guardian (https://ibn.fm/7ihOZ). In describing this family of promising medicines, Delic Co-founder and CEO Matt Stang similarly highlighted their “potential to be more effective than traditional drugs with minimal side effects, giving people their best lives back.” Stang’s comments are contained in a recent announcement in which Delic, a company making a mark in the psychedelic wellness scene, reported the findings of a survey it had commissioned (https://ibn.fm/rV24B). According to the survey conducted by The Harris Poll, 65% of Americans who suffer from anxiety/depression/PTSD believe that psychedelic medicine (ketamine, psilocybin, and MDMA) should be made available to patients with treatment-resistant anxiety, depression, or PTSD. Additionally, 63% of Americans who have used prescription medications to treat anxiety/depression/PTSD noted that while the medication helped, they still experienced residual feelings of anxiety, depression, or PTSD. Eighteen percent also said the prescribed drugs worsened their condition or did not improve it at all. Eighty-three percent of Americans living with anxiety, depression, or PTSD would be open to pursuing alternative treatments proven to be more effective than prescription medication with fewer side effects. More specifically, 66%, 62%, and 56% would be open to pursuing treatment using ketamine, psilocybin, and MDMA, respectively, if each was proven more effective than prescription drugs with fewer side effects. “We are witnessing a silent crisis impacting people across the globe exacerbated by an ongoing pandemic, and the results of this survey should compel more medical professionals and lawmakers to support in-depth studies on the therapeutic benefits of psychedelic medicine,” added Stang. The survey was conducted online within the United States in early December among 2,037 adults aged 18 or older, 953 of whom suffer from anxiety/depression/PTSD. It was not based on probability sampling. Founded in 2018, Delic is a leader in new medicines and treatments for a modern world and is committed to providing education, research, and treatment options to the masses in the field of psychedelics through an umbrella of related businesses that includes the largest chain of psychedelic wellness clinics with Ketamine Wellness Centers (“KWC”) and Ketamine Infusion Centers (“KIC”); media properties Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on the R&D of psilocybin vaporization products; and Meet Delic, the largest psychedelic wellness event. For more information, visit the company’s website at www.DelicCorp.com and the Meet Delic conference website at www.MeetDelic.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

• CNS Pharmaceuticals received approval from swissethics for its potentially pivotal study of Berubicin, a novel anthracycline for the treatment of Glioblastoma Multiforme (“GBM”)
• The approval is the first from a European Ethics Committee
• The company, which dosed the first patients in its Berubicin program in September, has selected multiple clinical sites across the U.S., Spain, France, Italy, and Switzerland
• CNS recently closed an $11.5 million private placement
• It intends to use the net proceeds to fund its clinical trials and preclinical programs, other R&D programs, and for general corporate purposes

Clinical stage biotechnology company CNS Pharmaceuticals (NASDAQ: CNSP) is celebrating a significant milestone as it journeys toward its potentially pivotal study of Berubicin for the treatment of Glioblastoma Multiforme (“GBM”). The company announced December 2 that it had received approval from swissethics, the umbrella organization of the cantonal Ethics Committees in Switzerland (https://ibn.fm/NisfL). The first from a European Ethics Committee, the approval partly fulfills CNS’s goal of seeing Berubicin approved for the potential treatment of GBM globally. “This terrible disease does not discriminate on the basis of geography or anything else: Patients in Europe are as desperate as patients in the United States, and treating patients is not only why we do what we do, but how we do it as well. Driving patient enrollment is how we advance Berubicin’s development, and opening additional clinical sites around the globe is the pivotal piece that allows us to ramp up our efforts and move toward data,” stated CNC Pharmaceuticals CEO John Climaco. So far, the company has selected tens of clinical sites across the United States, Spain, France, Italy, and Switzerland. In addition, CNS has already dosed the first patients in its Berubicin clinical development program, with a September 30, 2021 announcement noting that additional patient enrollment, randomization, and dosing was well underway in the United States (https://ibn.fm/qI7q2). Berubicin mid last year received the U.S. Food and Drug Administration (“FDA”) Fast Track Designation as well as an Orphan Drug Designation (https://ibn.fm/PSSiU). Notably, the former designation helps facilitate the development and expedited review of drugs with the potential of treating serious conditions with high unmet medical needs, thereby underlining the seriousness of GBM, one of the most aggressive, deadly, and treatment-resistant cancers that form in the brain. While chemotherapy medications are usually prescribed to patients living with the condition, results are underwhelming, if not devastating. According to CNS, the current standard of care is ineffective in about 60% of patients. GBM is the most common malignant brain and central nervous system tumor accounting for 47.7% of all cases, according to data from the American Association of Neurological Surgeons (“AANS”). Its prevalence within a population of 100,000 people stands at 3.21. But despite this low incidence rate, the disease is lethal – only 40% of patients survive in the first year after diagnosis and 17% in the second year. Moreover, it can cause death in six months or less (https://ibn.fm/wU6vY). In this regard, the recent approval, as well as CNS’s dosing efforts, offer a robust foundation for a potentially pivotal global trial. The adaptive, multicenter, open-level, randomized, and controlled study will evaluate Berubicin in adult patients with recurrent GBM (WHO Grade IV) after failure of standard first-line therapy. About 243 patients with GBM after failure of standard first-line therapy will be randomized in a 2:1 ratio to receive Berubicin or lomustine, a chemotherapy drug, in order to evaluate overall survival, the primary endpoint of the study. It is noteworthy that Berubicin is the first anthracycline to cross the blood-brain barrier. It evidences effectiveness in treating GBM. “[Anthracycline] is a classic drug that’s been around for 60 years. It’s the first line therapeutic for all sorts of difficult-to-treat cancers. But no one has been able to get a drug like this across the blood-brain barrier until our Founder modified the classic anthracycline molecule to be more effective in crossing the blood-brain barrier,” said Climaco during an October interview with Proactive (https://ibn.fm/EJjMb). Meanwhile, CNS Pharmaceuticals recently closed a previously announced private placement, priced at-the-market under Nasdaq rules, of over 12,105,264 shares of common stock (or pre-funded warrants in lieu thereof), raising gross proceeds of $11.5 million (before deductions). CNS intends to use the net proceeds to fund its clinical trials and preclinical programs, other R&D operations, and for general corporate purposes (https://ibn.fm/aTRJE). For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• FuelPositive has hit multiple milestones throughout 2021, starting with its rebranding in January that ushered it into the world of green hydrogen and ammonia
• In March, the company acquired the intellectual property for its green ammonia production technology
• In May, FuelPositive began building its prototype production systems in collaboration with the National Compressed Air in Toronto and is on track to launch multiple real-world demonstration pilot projects throughout 2022
• The modular, scalable green ammonia production systems offer numerous benefits, including zero carbon emissions and cheaper production costs than traditional grey ammonia production

On January 19, 2021, shareholders, during the annual general and special meeting, approved the rebranding of EEStor Corporation as FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) (https://ibn.fm/IY2z2), ushering the company into the rapidly burgeoning global hydrogen economy and subsequently into the green ammonia (“NH3”) segment, expected to grow at a 54% CAGR between 2020 and 2025 (https://ibn.fm/Fj9kO). Since then, FuelPositive has maintained a laser focus, driven by the mission to become a leader in fighting climate change by creating and developing practical, clean, and sustainable carbon-free solutions that can be implemented economically and at present. Its flagship offering – a proprietary, modular, scalable system that uses sustainable energy to produce green ammonia by combining nitrogen from the air with hydrogen extracted from water using a sustainable source of electricity – is intended to solve numerous problems, including the difficulty in storing and transporting hydrogen as well as the carbon emissions associated with traditional (“grey”) ammonia production. FuelPositive added this green ammonia production technology, a brainchild of Dr. Ibrahim Dincer and his research team at Ontario Tech University, to its intellectual property (“IP”) portfolio in March 2021 following an IP purchase agreement. “In May, we formed our manufacturing partnership with National Compressed Air to build our prototype systems; in June, we filed for our provisional patent and began to build our prototype production systems. Since then, we have raised over CA$12 million, which will cover our costs to build a number of green NH3 production systems. We are on track to launch multiple real-world demonstration pilot projects to showcase our technology throughout 2022,” said FuelPositive CEO and Board Chair Ian Clifford in a November 18 corporate update in which the company released an operational costing model and the timeline for its green ammonia technology (https://ibn.fm/STwU1). As part of the update, and based on a case study conducted in Manitoba, Canada, FuelPositive noted the green anhydrous ammonia produced by its system is about 40% cheaper to an end-user than grey ammonia. Accordingly, it offers additional benefits such as independence from the wildly volatile supply chain associated with grey anhydrous ammonia; on-site production that can be scaled depending on the demand and requirements; and a stable, predictable, and highly competitive cost per metric ton of producing green ammonia compared with the delivery price of an equivalent quantity of grey anhydrous ammonia. The company’s green ammonia system is transportable and modular, built to shipping container configurations – 20- and 40-foot containers, consumes less energy than conventional ammonia production, and does not have a carbon footprint. And as Clifford reiterated during a recent interview with The Tactical Leader Podcast, the company’s commitment to sustainability and environmental preservation extends beyond just producing green ammonia:  “. . . we look seriously at the impact of every step of our technology, not just the outcome of the product being carbon-free or non-polluting,” said Clifford. “Where does the steel come from that builds our systems? Where are the different technologies sourced? Where are the different raw materials from? It’s a real ‘cradle to cradle’ attitude in terms of our impact.” (https://ibn.fm/akJj7). Clifford also touched on the various applications of green ammonia, including as a fertilizer in the agriculture sector, fossil fuel replacement for the transportation sector, and a hydrogen storage medium (energy storage). In addition, 2021 represented remarkable milestones regarding the company’s engagement with investors and shareholders. In July, FuelPositive common shares debuted on the OTCQB Venture Marketplace, presenting a unique opportunity to increase its investor audience, visibility, and liquidity (https://ibn.fm/ToQXC). Similarly, FuelPositive participated in the H.C. Wainwright 23rd Annual Global Investment Conference held September 13-15, 2021. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF